You are now leaving the current website.

The site you are accessing is maintained by a third party over whom CSL Behring has no control. CSL Behring does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site. CSL Behring is not responsible for third-party content or the consequences of your use thereof.

Do you want to continue?

search-icon
search-icon
hemgenix-logo-bg mobile-menu-bg HEMGENIX® (etranacogene dezaparvovec-drlb)

Support for every step
of treatment and beyond

Support for every step of treatment and beyond

hemgenix connect logo

Dedicated experts offer information, support, and guidance

After speaking with your doctor about treatment with HEMGENIX, enroll to start taking advantage of the support HEMGENIX Connect offers, such as financial assistance programs, including copay assistance for eligible people with commercial insurance.*

Photo of young adult male

Join HEMGENIX Connect today!

Enroll now

Or call 1-833-436-0021 Monday through Friday, 8 AM-8 PM ET.

“HEMGENIX Connect took a lot of the stress off of me.”

-Michael, Actual HEMGENIX patient. Patient experiences may vary.

*See terms and conditions.

Elevate your expectations for support with HEMGENIX Connect, including:

Team icon

Your dedicated team, including a Patient Resource Navigator and a CSL Case Manager

Copay card icon

Financial assistance programs, including copay assistance for eligible people with commercial insurance*

Circle icon

Determination of eligibility for financial assistance programs

Magnifying glass icon

Insurance assessment to investigate coverage and explain your benefits

Computer monitor icon

Eligible HEMGENIX candidates can get support for screening tests, product administration, and required post-monitoring

Map pin drop icon

Logistics and travel support for required appointments are available

*See terms and conditions.

Robust commercial coverage and financial benefits

HEMGENIX is commonly billed under your medical benefit.

This means your benefits, copay, and coverage requirements are handled differently than traditional factor IX infusions.

HEMGENIX Connect can help provide out-of-pocket support

Eligible HEMGENIX candidates can get support for screening tests, product administration, and required post-monitoring.

Many US insurance companies and policies cover HEMGENIX† including:

Icon of checkmark

Commercial

Icon of checkmark

Medicaid

Icon of checkmark

Medicare

$0 out-of-pocket cost* for most commercially insured people

*Subject to terms and conditions of the Copay Support Program.
†Data provided by MMIT. Accessed May 13, 2024.

Early enrollment in HEMGENIX Connect will allow us to help you from the start! This enables your Patient Resource Navigator to provide education on gene therapy and your CSL Case Manager to investigate reimbursement support as early as possible.

HEMGENIX Connect℠ brochure thumbnail

HEMGENIX Connect Brochure

Provides additional information on the HEMGENIX Connect patient support program and lets you know what to expect during the treatment journey

Download

Patient Resource Navigator

Gene therapy for hemophilia B is an exciting innovation that could change how you think about living with hemophilia B. When you join HEMGENIX Connect, your dedicated Patient Resource Navigator will be your point of contact for educational resources and comprehensive support throughout every step of treatment with HEMGENIX.

Your Patient Resource Navigator will:

Checkmark icon

Provide education on gene therapy and how it works

Checkmark icon

Provide support and guidance on HEMGENIX treatment steps

Checkmark icon

Work hand in hand with your CSL Case Manager to help you learn about all possible sources of financial assistance and support

Woman standing with compass icon

Your Patient Resource Navigator will not provide personal medical advice. Please refer all questions about your individual health needs to your treating physician.

2 men talking

Patient portrayal

CSL Case Manager

Your dedicated team also includes a CSL Case Manager who will work directly with your Patient Resource Navigator.

Your CSL Case Manager can help:

Checkmark icon

Review your insurance, investigate coverage for treatment, and explain your benefits

Checkmark icon

Determine your eligibility for financial assistance programs

Checkmark icon

Identify the closest in-network administration center

Checkmark icon

Identify if copay assistance may be able to cover out-of-pocket expenses

Looking for a center that can infuse HEMGENIX?

Enter your ZIP code, city, or state to find the closest HEMGENIX administration center.

Discover other people who have experience with hemophilia B

Advocacy groups can help educate, connect, and empower people with hemophilia B and their families. Check out these national organizations for continued learning and support:

The Coalition for Hemophilia B Learn more
National Bleeding Disorders Foundation | formerly NHF Learn more
Hemophilia Federation of America Learn more

Explore gene therapy with HEMGENIX

Whether you have hemophilia B, are caring for someone with hemophilia B, or just want to learn more about HEMGENIX, we want to provide you with the information you need.

Sign up today

Downloadable support tools and resources are available

Go to HEMGENIX resources

Watch a real patient describe his HEMGENIX experience

Watch video
Amelia
Virtual Assistant
Hello, I am Amelia. How can I help you today? If this is a medical emergency, please call 911 or report to your local emergency room.
toggle chat overlay toggle chat overlay
Top of Page

IMPORTANT SAFETY INFORMATION

Before you can receive HEMGENIX®, etranacogene dezaparvovec-drlb, your doctor will perform tests to check for Factor IX inhibitors. If you have inhibitors, or have had them in the past, you are not a candidate for HEMGENIX. Your doctor will also check your liver health and screen for hepatitis B and C, as active infection may affect how well the treatment works or increase the risk of side effects.

Infusion-related and allergic reactions (including anaphylaxis) can occur. You will be monitored throughout infusion and for at least 3 hours afterward. If a reaction occurs during infusion, the infusion may be slowed or interrupted as symptoms are addressed, then started at a slower rate once symptoms have resolved.

Liver effects including liver injury can occur. Your doctor will monitor your liver with blood tests every week for 3 months and then monthly up to 1 year after treatment. Increased liver enzymes may require corticosteroid treatment. Because HEMGENIX works in the liver, there is a potential (possible but not proven) risk of liver cancer, and some patients may be monitored for up to 5 years.

After treatment, your body will develop antibodies to HEMGENIX, which may affect how well it works.

Your doctor will monitor Factor IX levels and check for inhibitors. You may still need support to help control bleeding, especially in the initial weeks after treatment.

Most common side effects include increased liver enzymes, headache, increased blood creatine kinase, flu-like symptoms, infusion-related reactions, fatigue, nausea, and feeling unwell. These are not the only side effects possible. Tell your healthcare provider about any side effect you may experience.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring’s Pharmacovigilance Department at 1-866-915-6958.

INDICATION

HEMGENIX is indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who:

  • Currently use Factor IX prophylaxis therapy, or
  • Have current or historical life-threatening hemorrhage, or
  • Have repeated, serious spontaneous bleeding episodes.

Please see full prescribing information for HEMGENIX.